Compare Prudential PLC (PUK) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential PLC vs 10X Genomics Inc — how do they compare? Prudential PLC trades at $27.1 (market cap $34.05B), while 10X Genomics Inc trades at $67.8 (market cap $8.55B). The key difference: Prudential PLC is far larger — about 4× 10X Genomics Inc's market cap, and Prudential PLC pays a 2.03% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| PUK | TXG | |
|---|---|---|
Market Cap | $34.05B | $8.55B |
Sector | Financials | Health |
52-Week High | $33.61 | $67.29 |
52-Week Low | $24.98 | $11.34 |
Enterprise Value | $33.60B | $8.08B |
Dividend Yield | 2.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prudential (PUK) trades at $27.42, down 1.19% with bearish technical signals but strong fundamentals including 14.52% net margin and 19.24% ROE. Recent earnings show mixed results with Q2 2026 missing expectations while maintaining revenue growth to $27.4B in 2025. The company demonstrates improved cash flow generation with $1.93B net cash flow in 2025 and continues shareholder returns through dividends.
The stock presents value with a 9.64 P/E ratio amid analyst optimism (50% buy ratings), though China regulatory risks and technical bearishness warrant caution. Long-term growth prospects in Asian markets and capital return initiatives support investment case, but investors should monitor execution of the five-year strategic reshaping plan.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
